David Musket Biography and Net Worth

Director of Capricor Therapeutics

Mr. Musket has been a member of the Capricor, Inc. Board since 2012 and a member of the Company’s Board since November 2013. He is Chairman of the Company’s Audit and Compensation Committees. Mr. Musket has vast experience in strategic finance and has been following developments in the pharmaceutical and medical device industries for over 30 years. Mr. Musket began his investment career as an equities research analyst at Goldman Sachs & Co. following the pharmaceutical industry. From 1991 through 2016 he served as President of Musket Research Associates, a registered broker/dealer focused exclusively on venture banking transactions for emerging healthcare companies. From 1996 to 2022 he was a General Partner of ProMed Management, a healthcare-focused investment management company. He has served on the boards of several private and public companies throughout his career. From 1999 to 2007, Mr. Musket served on the board of directors of publicly-traded Conor MedSystems, Inc. a medical device company sold to Johnson & Johnson in 2007 for $1.4 billion. Mr. Musket holds a Bachelor of Arts degree in Biology and Psychology from Boston College.

What is David B. Musket's net worth?: The estimated net worth of David B. Musket is at least $801.01 thousand as of October 12th, 2023. Musket owns 31,536 shares of Capricor Therapeutics stock worth more than $801,014 as of December 5th. This net worth evaluation does not reflect any other investments that Musket may own. Learn More about David B. Musket's net worth.
How do I contact David B. Musket?: The corporate mailing address for Musket and other Capricor Therapeutics executives is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. Capricor Therapeutics can also be reached via phone at 310-358-3200 and via email at [email protected]. Learn More on David B. Musket's contact information.
Has David B. Musket been buying or selling shares of Capricor Therapeutics?: David B. Musket has not been actively trading shares of Capricor Therapeutics within the last three months. Most recently, on Thursday, October 12th, David B. Musket bought 410 shares of Capricor Therapeutics stock. The stock was acquired at an average cost of $2.75 per share, with a total value of $1,127.50. Following the completion of the transaction, the director now directly owns 31,536 shares of the company's stock, valued at $86,724. Learn More on David B. Musket's trading history.
Who are Capricor Therapeutics' active insiders?: Capricor Therapeutics' insider roster includes Paul Auwaerter (Director), and David Musket (Director). Learn More on Capricor Therapeutics' active insiders.

David B. Musket Insider Trading History at Capricor Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/12/2023	Buy	410	$2.75	$1,127.50	31,536
10/9/2023	Buy	5,083	$2.82	$14,334.06	31,126
10/4/2023	Buy	2,500	$2.90	$7,250.00	26,043
6/29/2022	Sell	28,215	$3.77	$106,370.55	12,747
6/27/2022	Sell	17,775	$4.44	$78,921.00	40,962

David B. Musket Buying and Selling Activity at Capricor Therapeutics

Capricor Therapeutics Company Overview

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Today's Range

Now: $25.40

$23.05

$30.60

50 Day Range

MA: $7.19

$4.60

$29.96

2 Week Range

Now: $25.40

$4.30

$40.37

Volume

8,600,250 shs

Average Volume

5,002,246 shs

Market Capitalization

$1.16 billion

P/E Ratio

N/A

Dividend Yield